

WEIGHT MANAGEMENT & OBESITY

Prepared by:

CPL Business Consultants
Innovation Centre, Milton Park, Abingdon, Oxfordshire, OX14 4RY
Tel: +44 1491 822 844, info@cplconsult.com, www.cplconsult.com

Dr Robert Harwood
Dr Esther Hunter
Dr Steve Lisansky
Mr Mattias Bergstrom

STRATEGIES TO GROW YOUR BUSINESS

TABLE OF CONTENTS

OBJECTIVE	4
BACKGROUND	4
PRINCIPAL FINDINGS.....	5
OBESITY.....	5
PHARMACEUTICAL AND OTC	5
DIETARY SUPPLEMENTS.....	10
CONCLUSIONS	12
PHARMACEUTICAL & OTC	12
<i>General Plus Points about Pharmaceuticals & OTC</i>	<i>13</i>
<i>General Minus Points about Pharmaceutical & OTC.....</i>	<i>13</i>
<i>Plus points for Client about Pharmaceuticals & OTC.....</i>	<i>14</i>
<i>Minus Points for Client about Pharmaceuticals & OTC.....</i>	<i>14</i>
<i>Barriers to Entry in Pharmaceuticals and OTC.....</i>	<i>14</i>
<i>Key Success Factors in Pharmaceuticals and OTC</i>	<i>15</i>
DIETARY SUPPLEMENTS.....	15
<i>General Plus Points about Dietary Supplements</i>	<i>15</i>
<i>General Minus Points about Dietary Supplements.....</i>	<i>16</i>
<i>Plus points for Client about Dietary Supplements.....</i>	<i>16</i>
<i>Minus Points for Client about Dietary Supplements</i>	<i>17</i>
<i>Barriers to Entry in Supplements</i>	<i>17</i>
<i>Key Success Factors in Supplements.....</i>	<i>17</i>
RECOMMENDATIONS.....	18
PHARMACEUTICAL & OTC MARKET FOR WEIGHT CONTROL	19
MARKET.....	19
PRODUCTS & PLAYERS	20
<i>Types of Drugs Currently Used for Treating Obesity.....</i>	<i>20</i>
DRUGS IN THE PIPELINE	20
<i>Agents in Phase 2 of Clinical Development for Obesity.....</i>	<i>20</i>
<i>Agents in Phase 3 of Clinical Development for Obesity.....</i>	<i>21</i>
UK.....	21
<i>5 items</i>	
US.....	45
<i>1 item</i>	
NEWS	49
<i>8 items</i>	
GENERAL OVERVIEW OF THE GLOBAL PHARMACEUTICAL INDUSTRY	64
MARKET.....	64
MARKET FOR ACTIVE PHARMACEUTICAL INGREDIENTS (APIs)	67
MARKET TRENDS	69
THE DRUG DEVELOPMENT PROCESS.....	71
<i>Cost of developing a new medicine</i>	<i>71</i>
<i>Drug development and the conduct of medical research.....</i>	<i>72</i>
<i>Clinical trials.....</i>	<i>74</i>
<i>Success rates in Drug Development</i>	<i>77</i>
<i>The promotion of drugs</i>	<i>77</i>
<i>Market Penetration for New Drugs</i>	<i>78</i>
<i>Historical Data.....</i>	<i>79</i>
INTELLECTUAL PROPERTY PROTECTION	80
<i>Procedures for Drug Approval.....</i>	<i>80</i>
PLAYERS	81
<i>5 companies</i>	
THE PHARMACEUTICAL INDUSTRY BY REGION.....	97

<i>The US Pharmaceutical Industry</i>	97
<i>The European Pharmaceutical Industry</i>	98
<i>US vs. Europe - Competitive Comparison</i>	118
<i>The Pharmaceutical Industry in the ROW</i>	120
DIETARY SUPPLEMENT MARKET FOR WEIGHT CONTROL	129
INTRODUCTION	129
THE MARKET	130
<i>Trends</i>	132
<i>The market for appetite suppressants</i>	133
PRODUCTS, PLAYERS AND PRICES	133
<i>3 companies</i>	
NEWS	145
<i>9 items</i>	
GENERAL OVERVIEW OF THE GLOBAL DIETARY SUPPLEMENTS INDUSTRY	157
MARKETS.....	157
<i>Value</i>	157
<i>Market Drivers</i>	158
<i>Market Structure</i>	159
<i>Distribution Channels</i>	160
<i>Product and Brand Differentiation</i>	162
<i>Success Factors</i>	162
<i>Barriers to Entry</i>	163
PRODUCTS.....	165
<i>Definitions</i>	165
<i>Product Categories</i>	165
<i>Common dietary supplements and their benefits</i>	167
MAIN PLAYERS	170
<i>US</i>	170
<i>EU</i>	172
REGULATORY	174
<i>US</i>	174
<i>EU</i>	178
IP FOR THE USE OF HPMC IN LOWERING CHOLESTEROL	180
<i>Lowering blood cholesterol levels using cellulose ethers</i>	180
<i>Compositions Containing Low Viscosity Hydroxypropyl Methyl Cellulose for Lowering Blood Cholesterol Levels</i>	182
<i>Oral Depressant against Cholesterol</i>	182
<i>Palatable Hydroxypropyl Methylcellulose Ether Powder with Specified Particle Size</i>	183
OBESITY STATISTICS	184

TABLES

TABLE 1	GLOBAL PHARMACEUTICAL MARKET, \$B	65
TABLE 2	SIZE OF THE PHARMACEUTICAL MARKET \$B	79
TABLE 3	LARGEST PHARMACEUTICAL MARKETS \$M.....	79
TABLE 4	MARKET CONSOLIDATION IN THE GLOBAL PHARMACEUTICAL INDUSTRY	81
TABLE 5	THE EU PHARMACEUTICAL INDUSTRY IN FIGURES	98
TABLE 6	RESEARCH AND DEVELOPMENT IN THE EU PHARMACEUTICAL INDUSTRY	99
TABLE 7	THE PHARMACEUTICAL MARKET IN EUROPE, €B	99
TABLE 8	MARKET SIZE FOR THE CHILEAN PHARMACEUTICAL INDUSTRY, \$M	125
TABLE 9	SLIMMING PRODUCT MARKET BY COUNTRY (\$B)	130
TABLE 10	GLOBAL TOTAL WEIGHT MANAGEMENT MARKET BY REGION (\$B)	131
TABLE 11	COMMON SUPPLEMENTS FOR WEIGHT LOSS	134

TABLE 12	AN OVERVIEW OF SUPPLEMENT INGREDIENTS FOR WEIGHT MANAGEMENT	137
TABLE 13	MARKET CONCENTRATION IN THE DIETARY SUPPLEMENT INDUSTRY IN THE US	159
TABLE 14	US DIETARY SUPPLEMENT MARKET BY MANUFACTURER / MARKETER	160
TABLE 15	LIST OF DIETARY SUPPLEMENT PRODUCT CATEGORIES	165
TABLE 16	THE MOST COMMON DIETARY SUPPLEMENTS AND THEIR BENEFITS	167
TABLE 17	MEAN BODY MASS INDEX BY SEX, ADULTS AGED 15 AND OVER, AND PROJECTIONS, EUROPE.	184
TABLE 18	PREVALENCE ESTIMATES OF OVERWEIGHT AND OBESITY, AND PROJECTIONS, BY SEX, ADULTS AGED 15 AND OVER, THE WORLD	186

FIGURES

FIGURE 1	COST OF DEVELOPING A NEW MEDICINE	72
FIGURE 2	DEVELOPMENT OF A DRUG FROM TARGET IDENTIFICATION TO POST-LAUNCH PRODUCT REVIEW	75
FIGURE 3	NEW MOLECULAR ENTITIES APPROVED IN THE US	75
FIGURE 4	SUCCESS RATES IN DRUG DEVELOPMENT.....	77
FIGURE 5	PERCENTAGE MARKET SHARE FOR PRODUCTS LAUNCHED IN THE LAST FIVE YEARS	79
FIGURE 6	PHARMACEUTICAL INDUSTRY EXPENDITURE IN R&D IN EUROPE	99
FIGURE 7	SPLIT OF EUROPEAN PHARMACEUTICAL MARKET	100
FIGURE 8	FUNDING OF HEALTH-RELATED R&D IN THE UK.....	106
FIGURE 9	COMPARISON OF SHARE OF GLOBAL PHARMACEUTICAL R&D INVESTMENT	107
FIGURE 10	OBESITY AS % OF TOTAL POPULATION IN THE US	129
FIGURE 11	US WEIGHT MANAGEMENT MARKET BY CATEGORY	132
FIGURE 12	US DIETARY SUPPLEMENT MARKET BY CATEGORY	157
FIGURE 13	US DIETARY SUPPLEMENT SALES BY MARKET CHANNEL	161